Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma

Cell Research

Volumn 18, Issue 7, 2008, Pages 780-791

  Huang, Yan ^a   Hua, Keqin ^a   Zhou, Xianrong ^a   Jin, Hongyan ^a   Chen, Xiaojun ^a   Lu, Xin ^a   Yu, Yinhua ^b   Zha, Xiliang ^a   Feng, Youji ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

FSH; Ovarian serous cystadenocarcinoma; PI3K AKT signal transduction pathway; Survivin; VEGF

Indexed keywords

BIRC5 PROTEIN, HUMAN; FOLLITROPIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICROTUBULE ASSOCIATED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR PROTEIN; VASCULOTROPIN A;

ADULT; ARTICLE; CYSTADENOCARCINOMA; FEMALE; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 46749092963     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2008.70     Document Type: Article

References (48)

1. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5:19-24.
2. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144:363-372.
3. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280:C1358-C1366.
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-660.
5. Anonynous. Translational research: the role of VEGF in tumor angiogenesis. Proceedings of a symposium. Oncologist 2000; 5:1-57.
6. Xia C, Meng Q, Cao Z, et al. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol 2006; 209:56-66.
7. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004; 279:45643-45651.
8. Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 2003; 36:120-127.
9. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17:2115-2117.
10. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006; 66:3197-3204.
11. Ding J, Li J, Chen J, et al. Effects of polycyclic aromatic hydrocarbons (PAHs) on vascular endothelial growth factor induction through phosphatidylinositol 3-kinase/AP-1-dependent, HIF-1alpha-independent pathway. J Biol Chem 2006; 281:9093-9100.
12. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22:8581-8589.
13. Conway EM, Zwerts F, Van Eygen V, et al. Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol 2003; 163:935-946.
14. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001; 158:1757-1765.
15. O'Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156:393-398.
16. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6:127-134.
17. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in vitro fertilization. Lancet 1999; 354:1586-1590.
18. Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer, Curr Obstet Gynecol 2003; 15:63-68.
19. Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 1998; 25:255-264.
20. Gnagy S, Ming EE, Devesa SS, et al. Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology 2000; 11:102-105.
21. Zheng W, Lu JJ, Luo F, et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000; 76:80-88.
22. Parrott JA, Doraiswamy V, Kim G, et al. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001; 172:213-222.
23. Halperin R, Pansky M, Vaknin Z, et al. Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2003; 110:207-210.
24. 3az A, Kosmowska B. FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer 2004; 11:315-321.
25. Syed V, Ulinski G, Mok SC, et al. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001; 61:6768-6776.
26. Choi KC, Kang SK, Tai CJ, et al. Follicle stimulating hormone activates mitrogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2002; 87:2245-2253.
27. Ohtani K, Sakamoto H, Kikuchi A, et al. Follicle-stimulating hormone promotes the growth of human epithelial ovarian cancer cells through the protein kinase C-mediated system. Cancer Lett 2001; 166:207-213.
28. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006; 66:3912-3920.
29. Stadel BV. Letter: the etiology and prevention of ovarian carcinoma cells. Cancer Res 2001; 61:8340-8346.
30. Feng YJ, Zhang XY, Ge BQ. Gonadotropins stimulate the proliferation of human epithelial ovarian cancer cell. Zhonghua Fu Chan Ke Za Zhi 1996; 31:166-168.
31. Zhu MW, Wu QY, Ge BQ, et al. The dose response of cell proliferation and secretion of CA125 II antigen to follicle stimulation hormone in ovarian cancer cell lines. Zhonghua Fu Chan Ke Za Zhi 1998; 33:225-226.
32. Ji Q, Liu PI, Chen PK, et al. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 2004; 112:803-814.
33. Choi JH, Choi KC, Auersperg N, et al. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2004; 89:5508-5516.
34. Schiffenbauer YS, Meir G, Maoz M, et al. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 2002; 84:296-302.
35. Schiffenbauer YS, Abramovitch R, Meir G, et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 1997; 94:13203-13208.
36. Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 2002; 97:163-167.
37. Huang CF, Liu DY, Shen K. Follicle stimulating hormone inhibits cisplatin induced apoptosis in ovarian cancer cells. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003; 25:447-450.
38. Huang CF, Liu DY, Xu WH, et al. Protective effect of follicle stimulating hormone on apoptosis of human epithelial ovarian cancer cell induced by cisplatin. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003; 25:443-446.
39. Alam H, Maizels ET, Park Y, et al. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 2004; 279:19431-19440.
40. Carvalho CR, Carvalheira JB, Lima MH, et al. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 2003; 144:638-647.
41. Meroni SB, Riera MF, Pellizzari EH, Galardo MN, Cigorraga SB. FSH activates phosphatidylinositol 3-kinase/protein kinase B signaling pathway in 20-day-old Sertoli cells independently of IGF-I. J Endocrinol 2004; 180:257-265.
42. Gebauer G, Peter AT, Onesime D, et al. Apoptosis of ovarian granulosa cells: correlation with the reduced activity of ERK-signaling module. J Cell Biochem 1999; 75:547-554.
43. Maizels ET, Cottom J, Jones JC, et al. Follicle stimulating hormone (FSH) activates the p38 mitogen-activated protein kinase pathway, including small heat shock protein phosphorylation and cell rounding in immature rat ovarian granulose cells. Endocrinology 1998; 139:3353-3356.
44. Choi JH, Choi KC, Auersperg N, et al. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer 2005; 12:407-421.
45. Syed V, Ulinski G, Mok SC, et al. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cell. J Natl Cancer Inst 2002; 94:617-629.
46. Vara JAF, Casado E, de Castro J, et al. PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 2004; 30:193-204.
47. Park BK, Zeng X, Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cell. Cancer Res 2001; 61:7647-7653.
48. Liu LZ, Hu XW, Xia C, et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 2006; 41:1521-1533.